TaoWeave, Inc. (TWAV) Financials

TWAV

Trailing 12 months to June 30, 2026

Revenue $2.5M +4.1% YoY

Net Income -$6.7M -108.4% YoY

Operating Cash Flow -$3.5M -38.8% YoY

Gross Profit $1.3M +85.4% YoY

Market Cap $4.7M as of Sep 16, 2026

Price / Sales 1.9x on $2.5M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.9x on $5.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TWAV SEC filings page.

TaoWeave, Inc. (TWAV) reported $2.5M in revenue over the twelve months to Jun 30, 2026, up 4.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TWAV FY2025 2026-08-29

A gross-margin rebound has not overcome a largely fixed operating-cost base, leaving the business dependent on financing while operations consume cash.

From FY2024 to FY2025, revenue was essentially flat while gross margin rose from 13.9% to 41.6%, pointing to a major cost-of-revenue or mix shift rather than scale-driven growth. Operating cash flow remained negative in FY2025, while net loss exceeded operating loss; together, the margin improvement did not translate into cash or bottom-line earnings.

The longer arc is contraction followed by a margin rebound: revenue fell from $7.7M in FY2021 to $2.4M in FY2025. Even after the recovery, FY2025 gross profit was $1.0M versus SG&A of $3.9M, so overhead remains the main operating hurdle.

The balance sheet is lightly debt-funded: FY2025 debt-to-equity was 0.2x and the current ratio was 6.9x, but those ratios do not mean the business funds itself internally. Financing cash inflow of $9.0M nearly matched investing outflow of $8.7M, showing that reported cash movement was shaped by capital raising alongside investment.

Financial Health Signals

Financial Health Score 43/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of TaoWeave, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

TaoWeave, Inc. held $2.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $3.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and TaoWeave, Inc. scores 27/100 among other emerging companies.

Dilution

TaoWeave, Inc. had 3M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and TaoWeave, Inc. scores 89/100 among other emerging companies.

R&D Intensity

TaoWeave, Inc. spent $10K on research and development in fiscal year 2025, which was 0.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and TaoWeave, Inc. scores 4/100 among other emerging companies.

Revenue Progress

TaoWeave, Inc. reported revenue of $2.4M in fiscal year 2025, against $2.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and TaoWeave, Inc. scores 19/100 among other emerging companies.

Burn Trend

TaoWeave, Inc.'s operations used $3.0M of cash in fiscal year 2025, against $3.4M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and TaoWeave, Inc. scores 44/100 among other emerging companies.

Balance Sheet

TaoWeave, Inc.'s cash, cash equivalents and investments came to $2.3M at the end of fiscal year 2025, against $1.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and TaoWeave, Inc. scores 74/100 among other emerging companies.

Altman Z-Score Distress

-38.14

TaoWeave, Inc. scores -38.14, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.7M) relative to total liabilities ($1.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

TaoWeave, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

TaoWeave, Inc. reported a net loss of $6.4M while operations used $3.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$522K

YoY-11.8%

QoQ-26.2%

5Y CAGR-23.9%

10Y CAGR-20.4%

TaoWeave, Inc. generated $522K in revenue in Q2 2026. This represents a decrease of 11.8% from the same quarter a year earlier. Against the prior quarter it is down 26.2%.

Net Income

-$3.3M

YoY-443.8%

QoQ-293.9%

TaoWeave, Inc. reported -$3.3M in net income in Q2 2026. This represents a decrease of 443.8% from the same quarter a year earlier. Against the prior quarter it is down 293.9%.

EBITDA

Not reported for Q2 2026.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$735K

YoY-93.2%

QoQ-65.5%

5Y CAGR-43.8%

10Y CAGR-6.8%

TaoWeave, Inc. held $735K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+65.0%

QoQ+12.2%

5Y CAGR-33.9%

10Y CAGR-19.9%

TaoWeave, Inc. had 4M shares outstanding in Q2 2026. This represents an increase of 65.0% from the same quarter a year earlier. Against the prior quarter it is up 12.2%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

52.5%

YoY+14.0pp

QoQ-14.0pp

5Y change+13.5pp

TaoWeave, Inc.'s gross margin was 52.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 14.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.0 percentage points.

Return on Equity

-59.9%

YoY-54.5pp

QoQ-79.4pp

5Y change-52.0pp

10Y change-49.0pp

TaoWeave, Inc.'s ROE was -59.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 54.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 79.4 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

YoY-100.0%

TaoWeave, Inc. reported no research and development spending in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

TWAV Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TWAV quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$2.5M	$2.4M+2.5%	$2.4M-37.6%	$3.8M-30.4%	$5.5M-29.2%	$7.7M-49.5%	$15.3M+19.5%	$12.8M+2.2%	$12.6M-15.1%	$14.8M-23.0%	$19.2M-24.8%	$25.5M-20.6%	$32.2M-3.9%	$33.5M+15.1%	$29.1M+4.5%	$27.8M
Cost of Revenue	$1.2M	$1.4M-30.5%	$2.0M-29.4%	$2.9M-26.2%	$3.9M-21.7%	$5.0M-31.0%	$7.3M-2.0%	$7.4M-2.3%	$7.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$1.3M	$1.0M+206.3%	$331K-63.7%	$911K-41.1%	$1.5M-43.1%	$2.7M-66.2%	$8.1M+49.1%	$5.4M+8.9%	$5.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4K	$10K-93.5%	$155K+675.0%	$20K-98.8%	$1.7M-41.7%	$2.9M-21.5%	$3.7M+83.4%	$2.0M+119.7%	$921K-19.8%	$1.1M	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$4.3M	$3.9M-6.0%	$4.2M-13.8%	$4.9M-7.7%	$5.3M-17.1%	$6.4M-5.4%	$6.7M+25.1%	$5.4M+16.6%	$4.6M+25.8%	$3.7M-29.6%	$5.2M-3.9%	$5.4M-4.0%	$5.6M-23.5%	$7.4M+15.1%	$6.4M+13.3%	$5.7M
Operating Income	-$3.0M	-$3.0M+29.5%	-$4.2M+6.5%	-$4.5M+79.6%	-$22.0M-86.4%	-$11.8M-17.2%	-$10.1M-32.9%	-$7.6M-12.4%	-$6.7M-184.7%	-$2.4M-13.5%	-$2.1M-326.4%	-$489K+58.7%	-$1.2M+17.9%	-$1.4M-141.9%	-$596K-226.8%	$470K
EBITDA	N/A	N/A	-$4.2M-1.3%	-$4.2M+79.3%	-$20.1M-121.7%	-$9.1M-30.8%	-$6.9M-10.7%	-$6.3M-4.5%	-$6.0M-702.3%	-$746K-492.1%	-$126K-107.2%	$1.7M+12.6%	$1.6M+9.4%	$1.4M-4.8%	$1.5M-21.9%	$1.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$311K-69.4%	$1.0M-30.1%	$1.5M+4.2%	$1.4M+4.0%	$1.3M+22.5%	$1.1M+160.3%	$421K+528.4%	$67K
Income Tax	-$4K	$2K-80.0%	$10K-63.0%	$27K+485.7%	-$7K+92.2%	-$90K-187.4%	$103K	$0-100.0%	$13K+105.7%	-$230K-191.1%	-$79K-146.5%	$170K+22.3%	$139K+563.3%	-$30K+98.6%	-$2.2M	$0
Net Income	-$6.7M	-$6.4M-57.2%	-$4.0M+7.8%	-$4.4M+80.0%	-$21.9M-142.4%	-$9.1M-22.0%	-$7.4M+4.4%	-$7.8M-8.3%	-$7.2M-223.9%	$5.8M+263.7%	-$3.5M-64.9%	-$2.1M+22.2%	-$2.8M+34.6%	-$4.2M-500.7%	$1.1M+184.8%	$369K
EPS (Basic)	N/A	-$2.76+82.4%	-$15.71+16.5%	-$18.81-77.1%	-$10.62-93.8%	-$5.48-270.3%	-$1.48	N/A	-$0.15-200.0%	$0.15+250.0%	-$0.10-66.7%	-$0.06+25.0%	-$0.08+42.9%	-$0.14-450.0%	$0.04+100.0%	$0.02
EPS (Diluted)	—	N/A	N/A	-$0.98	-$10.62	-$5.48	-$1.48	N/A	-$0.15-207.1%	$0.14+240.0%	-$0.10-66.7%	-$0.06+25.0%	-$0.08+42.9%	-$0.14-450.0%	$0.04+100.0%	$0.02
Diluted Shares (Avg)	N/A	N/A	N/A	6M	2M	2M	6M	5M	48M+15.7%	41M+16.4%	36M+0.5%	35M+1.6%	35M+14.3%	31M+14.5%	27M+14.1%	23M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$522K-11.8%	$707K+13.7%	$622K+10.5%	$601K+4.0%	$592K-3.1%	$622K-0.6%	$563K-40.4%	$578K-33.7%
Cost of Revenue	$248K-31.9%	$237K-36.5%	$329K-23.1%	$357K-28.5%	$364K-25.9%	$373K-40.7%	$428K-34.7%	$499K-23.0%
Gross Profit	$274K+20.2%	$470K+88.8%	$293K+117.0%	$244K+208.9%	$228K+90.0%	$249K+8400.0%	$135K-53.3%	$79K-64.7%
R&D Expenses	$0-100.0%	$0-100.0%	$1K-50.0%	$3K-92.1%	$3K-95.4%	$3K-94.0%	$2K-50.0%	$38K+660.0%
SG&A Expenses	$1.1M+23.6%	$1.0M+10.0%	$1.1M+1.3%	$1.0M-0.4%	$902K-11.2%	$929K-13.7%	$1.1M-7.8%	$1.0M+7.2%
Operating Income	-$841K-23.1%	-$559K+19.1%	-$786K+15.3%	-$802K+25.2%	-$683K+32.9%	-$691K+41.6%	-$928K+27.3%	-$1.1M-15.9%
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	-$928K+22.0%	-$1.1M-27.8%
Income Tax	$1K	$0-100.0%	-$5K-600.0%	$0	$0-100.0%	$7K	$1K+109.1%	$0
Net Income	-$3.3M-443.8%	$1.7M+352.5%	-$2.8M-215.4%	-$2.3M-120.2%	-$605K+38.5%	-$672K+40.8%	-$884K+27.6%	-$1.0M-16.2%
EPS (Basic)	-$0.84-121.1%	$0.43+172.9%	-$1.00-212.4%	-$0.74+93.4%	-$0.38+72.5%	-$0.59+70.8%	$0.89+48.3%	-$11.25-166.6%
EPS (Diluted)	N/A	$0.43	N/A	N/A	N/A	-$0.59	N/A	N/A
Diluted Shares (Avg)	N/A	4M	N/A	N/A	N/A	1M	N/A	N/A

Not reported in any period shown, so not listed: Interest Expense.

TWAV Balance Sheet

TWAV quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$8.2M+55.8%	$5.3M-23.8%	$6.9M+22.3%	$5.7M-80.2%	$28.6M-1.8%	$29.1M-16.5%	$34.9M+338.4%	$8.0M-48.4%	$15.4M-6.5%	$16.5M-17.6%	$20.0M-11.4%	$22.6M-12.6%	$25.9M-11.7%	$29.3M+209.7%	$9.5M
Current Assets	$8.2M+55.9%	$5.3M-23.6%	$6.9M+41.5%	$4.9M-61.8%	$12.8M+27.6%	$10.0M+0.7%	$9.9M+152.9%	$3.9M-33.3%	$5.9M+56.7%	$3.8M-25.2%	$5.0M-19.6%	$6.2M-8.0%	$6.8M-5.4%	$7.2M+53.4%	$4.7M
Cash & Equivalents	$2.3M-54.5%	$5.0M-17.1%	$6.0M+94.2%	$3.1M-65.7%	$9.0M+70.6%	$5.3M+14.7%	$4.6M+129.3%	$2.0M-49.1%	$3.9M+246.1%	$1.1M-35.4%	$1.8M-9.0%	$1.9M-15.5%	$2.3M+3.4%	$2.2M+22.0%	$1.8M
Short-Term Investments	$0	$0-100.0%	$500K	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$0	$0-100.0%	$239K-66.9%	$723K-60.3%	$1.8M+97.9%	$920K-49.3%	$1.8M	$0	N/A	N/A	N/A	N/A	$0-100.0%	$37K	$0
Accounts Receivable	$138K-25.8%	$186K-56.1%	$424K+2.2%	$415K-51.1%	$849K-73.2%	$3.2M+24.5%	$2.5M+85.5%	$1.4M+12.4%	$1.2M-25.4%	$1.6M-39.4%	$2.7M-17.6%	$3.3M-19.7%	$4.1M+0.7%	$4.0M+60.6%	$2.5M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	$0	$0	$0-100.0%	$7.4M0.0%	$7.4M-6.8%	$7.9M+182.9%	$2.8M-63.9%	$7.8M-16.0%	$9.2M-6.1%	$9.8M0.0%	$9.8M0.0%	$9.8M-0.8%	$9.9M	$0
Total Liabilities	$1.2M-6.8%	$1.3M-10.7%	$1.4M-30.3%	$2.0M-34.3%	$3.1M-56.1%	$7.1M-46.0%	$13.1M+1059.4%	$1.1M-64.2%	$3.2M-74.8%	$12.6M-7.9%	$13.7M-6.8%	$14.6M-9.7%	$16.2M-0.6%	$16.3M+260.5%	$4.5M
Current Liabilities	$1.2M-6.8%	$1.3M-9.0%	$1.4M-26.9%	$1.9M-23.3%	$2.5M-55.3%	$5.6M-32.5%	$8.3M+629.5%	$1.1M-59.5%	$2.8M-77.4%	$12.3M+348.1%	$2.8M-26.0%	$3.7M-37.3%	$5.9M-7.9%	$6.5M+53.9%	$4.2M
Non-Current Liabilities	$0	$0-100.0%	$26K-80.2%	$131K-78.8%	$617K-59.2%	$1.5M-68.9%	$4.9M	$0-100.0%	$369K+60.4%	$230K-97.9%	$10.9M-0.3%	$10.9M+6.3%	$10.3M+4.2%	$9.9M+2852.7%	$334K
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$403K-85.8%	$2.8M	$0-100.0%	$369K	$0-100.0%	$10.6M-1.8%	$10.8M+5.4%	$10.2M+6.3%	$9.6M	$0
Total Equity	$7.0M+75.7%	$4.0M-27.2%	$5.5M+52.0%	$3.6M-85.8%	$25.5M+15.6%	$22.1M+1.2%	$21.8M+219.0%	$6.8M-44.3%	$12.3M+212.2%	$3.9M-38.5%	$6.4M-19.9%	$8.0M-17.6%	$9.7M-25.6%	$13.0M+163.2%	$4.9M
Retained Earnings	-$238.6M-2.7%	-$232.3M-1.8%	-$228.2M-2.0%	-$223.8M-10.9%	-$201.9M-4.7%	-$192.9M-4.0%	-$185.4M-4.4%	-$177.7M-4.2%	-$170.5M+3.3%	-$176.3M-2.0%	-$172.8M-1.3%	-$170.6M-1.6%	-$167.9M-2.6%	-$163.6M+0.6%	-$164.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$6.8M-48.1%	$10.0M+109.8%	$8.2M+55.8%	$10.9M+81.8%	$13.1M+107.2%	$4.8M-19.9%	$5.3M-23.8%	$6.0M-24.9%
Current Assets	$5.7M-56.2%	$10.0M+110.0%	$8.2M+55.9%	$10.9M+82.0%	$13.1M+107.5%	$4.8M-19.8%	$5.3M-23.6%	$6.0M-21.0%
Cash & Equivalents	$735K-93.2%	$2.1M-50.6%	$2.3M-54.5%	$3.7M-33.5%	$10.8M+84.3%	$4.3M-19.5%	$5.0M-17.1%	$5.6M-17.0%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$0
Inventory	N/A	N/A	$0	N/A	N/A	N/A	$0-100.0%	$50K-84.6%
Accounts Receivable	$5K-66.7%	$135K+19.5%	$138K-25.8%	$12K-63.6%	$15K-51.6%	$113K+653.3%	$186K-56.1%	$33K-79.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Total Liabilities	$1.3M-29.1%	$1.3M-11.0%	$1.2M-6.8%	$1.1M-19.1%	$1.8M+44.6%	$1.4M-6.4%	$1.3M-10.7%	$1.3M+0.3%
Current Liabilities	$1.3M-29.1%	$1.3M-11.0%	$1.2M-6.8%	$1.1M-18.9%	$1.8M+45.3%	$1.4M-5.5%	$1.3M-9.0%	$1.3M+3.1%
Non-Current Liabilities	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$2K-94.7%
Total Equity	$5.5M-51.2%	$8.7M+160.5%	$7.0M+75.7%	$9.8M+110.3%	$11.3M+122.7%	$3.4M-24.4%	$4.0M-27.2%	$4.7M-29.9%
Retained Earnings	-$240.2M-2.9%	-$236.9M-1.7%	-$238.6M-2.7%	-$235.8M-1.9%	-$233.6M-1.4%	-$232.9M-1.6%	-$232.3M-1.8%	-$231.4M-1.9%

Not reported in any period shown, so not listed: Long-Term Debt.

TWAV Cash Flow Statement

TWAV quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$3.5M	-$3.0M+11.5%	-$3.4M-13.8%	-$3.0M+49.6%	-$5.9M+23.3%	-$7.7M-17.8%	-$6.6M-101.8%	-$3.3M-181.6%	-$1.2M-171.8%	$1.6M+779.2%	$183K-85.2%	$1.2M-30.7%	$1.8M-22.4%	$2.3M+180.1%	$821K+9.2%	$752K
Depreciation & Amortization	N/A	N/A	$0-100.0%	$345K-81.9%	$1.9M-30.4%	$2.7M-12.9%	$3.1M+137.7%	$1.3M+75.0%	$755K-53.4%	$1.6M-17.3%	$2.0M-12.3%	$2.2M-18.3%	$2.7M-4.4%	$2.9M+37.2%	$2.1M+45.2%	$1.4M
Stock-Based Compensation	N/A	$169K+172.6%	$62K-87.7%	$504K+245.2%	$146K-75.5%	$597K+201.5%	$198K+80.0%	$110K-69.9%	$365K-20.3%	$458K-50.7%	$929K+14.3%	$813K+35.5%	$600K-50.1%	$1.2M+77.4%	$678K+189.7%	$234K
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$11K-78.0%	$50K+31.6%	$38K-15.6%	$45K-86.6%	$335K+151.9%	$133K-65.2%	$382K-69.4%	$1.2M-42.7%	$2.2M+154.2%	$856K+15.7%	$740K-21.3%	$940K
Free Cash Flow	N/A	N/A	N/A	-$3.0M+49.7%	-$5.9M+23.6%	-$7.8M-17.8%	-$6.6M-100.2%	-$3.3M-121.3%	-$1.5M-200.9%	$1.5M+841.7%	-$199K-1890.0%	-$10K+97.4%	-$391K-127.1%	$1.4M+1682.7%	$81K+143.1%	-$188K
Investing Cash Flow	-$7.4M	-$8.7M	$0	$0-100.0%	$19K+138.8%	-$49K-58.1%	-$31K-101.4%	$2.1M+741.5%	-$335K-151.9%	-$133K+65.2%	-$382K+69.3%	-$1.2M+42.7%	-$2.2M-141.3%	-$900K+89.1%	-$8.3M-793.4%	-$928K
Financing Cash Flow	$846K	$9.0M+279.8%	$2.4M-59.6%	$5.9M	$0-100.0%	$11.5M+58.2%	$7.3M+96.6%	$3.7M+923.8%	-$449K-133.8%	$1.3M+412.9%	-$425K-154.5%	-$167K-638.7%	$31K+102.3%	-$1.3M-116.8%	$7.9M+19295.1%	-$41K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$51K-64.6%	$144K-93.8%	$2.3M+17784.6%	$13K-90.7%	$140K+112.1%	$66K	$0	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$539K-1356.8%	-$650K+4.4%	-$744K+15.9%	-$1.6M-70.6%	-$37K+96.2%	-$680K-7.9%	-$885K-25.5%	-$911K-759.4%
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$0-100.0%
Stock-Based Compensation	N/A	$84K	N/A	N/A	N/A	$0-100.0%	N/A	N/A
Investing Cash Flow	-$856K+48.1%	$522K	-$736K	-$6.3M	-$1.6M	$0	$0	$0
Financing Cash Flow	$0-100.0%	$0-100.0%	$0-100.0%	$846K+25.9%	$8.2M+452.5%	$31K	$231K+425.4%	$672K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

TWAV Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TWAV quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	41.6%+27.7pp	13.9%-10.0pp	23.9%-4.3pp	28.2%-6.9pp	35.1%-17.4pp	52.5%+10.4pp	42.1%+2.6pp	39.5%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-121.5%	-176.7%	-118.0%	-401.5%	-152.4%	-65.6%-6.6pp	-59.1%-5.4pp	-53.7%-37.7pp	-16.0%-5.1pp	-10.8%-8.9pp	-1.9%+1.8pp	-3.7%+0.6pp	-4.3%-2.3pp	-2.1%-3.7pp	1.7%
Net Margin	-260.8%	-170.0%	-115.1%	-400.7%	-117.0%	-48.4%+12.1pp	-60.5%-3.4pp	-57.1%-96.2pp	39.1%+57.5pp	-18.4%-10.0pp	-8.4%+0.2pp	-8.6%+4.0pp	-12.6%-16.2pp	3.6%+2.3pp	1.3%
Return on Equity	-90.4%+10.6pp	-101.0%-21.3pp	-79.7%+526.8pp	-606.4%-570.9pp	-35.5%-1.9pp	-33.6%+2.0pp	-35.6%+69.3pp	-105.0%-152.1pp	47.2%+137.1pp	-89.9%-56.4pp	-33.6%+1.0pp	-34.6%+9.0pp	-43.5%-51.6pp	8.1%+0.6pp	7.5%
Return on Assets	-77.3%-0.7pp	-76.6%-13.3pp	-63.3%+324.3pp	-387.6%-355.9pp	-31.6%-6.2pp	-25.5%-3.2pp	-22.2%+67.8pp	-90.0%-127.5pp	37.5%+58.9pp	-21.4%-10.7pp	-10.7%+1.5pp	-12.2%+4.1pp	-16.3%-19.9pp	3.6%-0.3pp	3.9%
Current Ratio	6.93+2.8x	4.14-0.8x	4.93+2.4x	2.55-2.6x	5.11+3.3x	1.79+0.6x	1.20-2.3x	3.47+1.4x	2.11+1.8x	0.30-1.5x	1.82+0.1x	1.68+0.5x	1.140.0x	1.110.0x	1.11
Debt-to-Equity	0.17-0.1x	0.32+0.1x	0.26-0.3x	0.56+0.6x	0.000.0x	0.02-0.1x	0.13+0.1x	0.000.0x	0.030.0x	0.00-1.7x	1.66+0.3x	1.35+0.3x	1.06+0.3x	0.74+0.7x	0.00
Asset Turnover	0.30-0.2x	0.45-0.1x	0.55-0.4x	0.97+0.7x	0.27-0.3x	0.53+0.2x	0.37-1.2x	1.58+0.6x	0.96-0.2x	1.16-0.1x	1.27-0.1x	1.42+0.1x	1.29+0.3x	0.99-1.9x	2.94
FCF Margin	N/A	N/A	-78.6%	-108.6%	-100.6%	-43.1%-17.4pp	-25.7%-13.8pp	-11.9%-21.8pp	10.0%+11.0pp	-1.0%-1.0pp	0.0%+1.2pp	-1.2%-5.5pp	4.3%+4.0pp	0.3%+1.0pp	-0.7%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	52.5%+14.0pp	66.5%+26.4pp	47.1%+23.1pp	40.6%+26.9pp	38.5%+18.9pp	40.0%+40.5pp	24.0%-6.6pp	13.7%-12.0pp
Operating Margin	-161.1%	-79.1%	-126.4%	-133.4%	-115.4%	-111.1%	-164.8%	-185.5%
Net Margin	-630.3%	240.0%	-448.2%	-381.0%	-102.2%	-108.0%	-157.0%	-179.9%
Return on Equity	-59.9%-54.5pp	19.4%+39.5pp	-39.6%-17.6pp	-23.3%-1.0pp	-5.4%+14.1pp	-20.1%+5.6pp	-22.1%+0.1pp	-22.3%-8.8pp
Return on Assets	-48.5%-43.9pp	17.0%+31.1pp	-33.9%-17.2pp	-21.0%-3.7pp	-4.6%+11.0pp	-14.1%+5.0pp	-16.8%+0.9pp	-17.3%-6.1pp
Current Ratio	4.45-2.8x	7.97+4.6x	6.93+2.8x	10.18+5.6x	7.21+2.2x	3.38-0.6x	4.14-0.8x	4.53-1.4x
Debt-to-Equity	0.23+0.1x	0.14-0.3x	0.17-0.1x	0.11-0.2x	0.16-0.1x	0.42+0.1x	0.32+0.1x	0.28+0.1x
Asset Turnover	0.080.0x	0.07-0.1x	0.080.0x	0.060.0x	0.05-0.1x	0.130.0x	0.110.0x	0.100.0x

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Where TaoWeave, Inc. Ranks

Frequently Asked Questions

What is TaoWeave, Inc.'s annual revenue?

TaoWeave, Inc. (TWAV) reported $2.4M in total revenue for fiscal year 2025. This represents a 2.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is TaoWeave, Inc.'s revenue growing?

TaoWeave, Inc. (TWAV) revenue grew by 2.5% year-over-year, from $2.4M to $2.4M in fiscal year 2025.

Is TaoWeave, Inc. profitable?

No, TaoWeave, Inc. (TWAV) reported a net income of -$6.4M in fiscal year 2025.

What is TaoWeave, Inc.'s gross margin?

TaoWeave, Inc. (TWAV) had a gross margin of 41.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is TaoWeave, Inc.'s return on equity (ROE)?

TaoWeave, Inc. (TWAV) has a return on equity of -90.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is TaoWeave, Inc.'s operating cash flow?

TaoWeave, Inc. (TWAV) recorded an outflow of $3.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are TaoWeave, Inc.'s total assets?

TaoWeave, Inc. (TWAV) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does TaoWeave, Inc. spend on research and development?

TaoWeave, Inc. (TWAV) invested $10K in research and development during fiscal year 2025.

How many shares does TaoWeave, Inc. have outstanding?

TaoWeave, Inc. (TWAV) had 3M shares outstanding as of fiscal year 2025.

What is TaoWeave, Inc.'s current ratio?

TaoWeave, Inc. (TWAV) had a current ratio of 6.93 as of fiscal year 2025, which is generally considered healthy.

What is TaoWeave, Inc.'s debt-to-equity ratio?

TaoWeave, Inc. (TWAV) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is TaoWeave, Inc.'s return on assets (ROA)?

TaoWeave, Inc. (TWAV) had a return on assets of -77.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is TaoWeave, Inc.'s P/E ratio?

TaoWeave, Inc. (TWAV) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $4.7M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is TaoWeave, Inc.'s price-to-sales ratio?

TaoWeave, Inc. (TWAV) trades at 1.9x sales, its market capitalization divided by revenue of $2.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $4.7M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is TaoWeave, Inc.'s Altman Z-Score?

TaoWeave, Inc. (TWAV) has an Altman Z-Score of -38.14, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is TaoWeave, Inc.'s Piotroski F-Score?

TaoWeave, Inc. (TWAV) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are TaoWeave, Inc.'s earnings high quality?

TaoWeave, Inc. (TWAV) reported a net loss of $6.4M while operations used $3.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is TaoWeave, Inc.?

TaoWeave, Inc. (TWAV) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.